RCG
CGTX icon

Rock Creek Group’s Cognition Therapeutics CGTX Stock Holding History

Rock Creek Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,222
Closed -$14.7K – 88
2023
Q3 		$14.7K Hold
10,222
– – ﹤0.01% 161
2023
Q2 		$18.7K Sell
10,222
-39,778
-80% -$84.2K ﹤0.01% 150
2023
Q1 		$99K Hold
50,000
– – 0.01% 127
2022
Q4 		$105K Hold
50,000
– – 0.01% 112
2022
Q3 		$95K Sell
50,000
-29,751
-37% -$62K 0.01% 116
2022
Q2 		$170K Buy
79,751
+53,312
+202% +$138K 0.02% 97
2022
Q1 		$71K Hold
26,439
– – 0.01% 134
2021
Q4 		$167K Buy
+26,439
New +$258K 0.02% 147

Other funds holding CGTX

Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Rock Creek Group's CGTX Position: Q4 2023 in Review

Rock Creek Group sold out of Cognition Therapeutics (CGTX) in Q4 2023, closing a stake of 10,222 shares — an estimated $14.7K sold.

Rock Creek Group first reported a position in CGTX in Q4 2021 and held it in 8 quarters. The position peaked at $170K in Q2 2022. 37 funds tracked by Wall St. Rank hold CGTX as of Q4 2023.

  • Rock Creek Group reported no remaining Cognition Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Rock Creek Group sold 10,222 Cognition Therapeutics shares in Q4 2023, an estimated $14.7K.
  • Rock Creek Group first reported a position in Cognition Therapeutics in Q4 2021 and held it in 8 quarters.
  • Rock Creek Group's Cognition Therapeutics position peaked at $170K in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2023.

Based on Rock Creek Group's 13F filing for Q4 2023, filed 13 Feb 2024.